{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:36:37Z","timestamp":1791606997421,"version":"4.3.4"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.eururo.2022.09.004","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T08:54:33Z","timestamp":1663059273000},"page":"224-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["B7-H3 as a Therapeutic Target in Advanced Prostate Cancer"],"prefix":"10.1016","volume":"83","author":[{"given":"Christina","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Gurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Neeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Seed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Carreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rekowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Buroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Welti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa","family":"Bogdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria D.","family":"Fenor de la Maza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Westaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khobe","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Riisnaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Cal\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Alimonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bressan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana H.T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E.","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Obradovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bertan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2022.09.004_b0005","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic prostate cancer","volume":"378","author":"Sartor","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.09.004_b0010","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2022.09.004_b0015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41568-020-0267-9","article-title":"Prostate carcinogenesis: inflammatory storms","volume":"20","author":"de Bono","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2022.09.004_b0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/pcan.2016.49","article-title":"Correlation of B7\u2013H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis","volume":"20","author":"Benzon","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2022.09.004_b0025","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1158\/0008-5472.CAN-07-1068","article-title":"B7\u2013H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy","volume":"67","author":"Roth","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2022.09.004_b0030","doi-asserted-by":"crossref","first-page":"19458","DOI":"10.1073\/pnas.0709802104","article-title":"B7\u2013H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome","volume":"104","author":"Zang","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2022.09.004_b0035","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.ajpath.2018.02.014","article-title":"Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer","volume":"188","author":"Haffner","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2022.09.004_b0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40364-021-00267-y","article-title":"Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomarker Res"},{"key":"10.1016\/j.eururo.2022.09.004_b0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0002-9440(10)62990-2","article-title":"The immunomodulatory proteins B7-DC, B7\u2013H2, and B7\u2013H3 are differentially expressed across gestation in the human placenta","volume":"167","author":"Petroff","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2022.09.004_b0050","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.4049\/jimmunol.172.4.2352","article-title":"Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains","volume":"172","author":"Steinberger","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.eururo.2022.09.004_b0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/85339","article-title":"B7\u2013H3: a costimulatory molecule for T cell activation and IFN-\u03b3 production","volume":"2","author":"Chapoval","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.eururo.2022.09.004_b0060","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1158\/1078-0432.CCR-08-2262","article-title":"Expression of immunosuppresive B7\u2013H3 ligand by hormone-treated prostate cancer tumors and metastases","volume":"15","author":"Chavin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2022.09.004_b0065","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/cr.2017.90","article-title":"Inhibition of the B7\u2013H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function","volume":"27","author":"Lee","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.eururo.2022.09.004_b0070","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.4049\/jimmunol.173.9.5445","article-title":"B7\u2013H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells","volume":"173","author":"Luo","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.eururo.2022.09.004_b0075","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.4049\/jimmunol.173.4.2500","article-title":"Murine B7\u2013H3 is a negative regulator of T cells","volume":"173","author":"Prasad","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.eururo.2022.09.004_b0080","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/ni967","article-title":"The B7 family member B7\u2013H3 preferentially down-regulates T helper type 1-mediated immune responses","volume":"4","author":"Suh","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.eururo.2022.09.004_b0085","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/eji.200425518","article-title":"B7\u2013H3 promotes acute and chronic allograft rejection","volume":"35","author":"Wang","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.eururo.2022.09.004_b0090","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/2326-6066.CIR-15-0100","article-title":"Ablation of B7\u2013H3 but not B7\u2013H4 results in highly increased tumor burden in a murine model of spontaneous prostate cancer","volume":"3","author":"Kreymborg","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.eururo.2022.09.004_b0095","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/sj.gt.3302070","article-title":"Mouse B7\u2013H3 induces antitumor immunity","volume":"10","author":"Sun","year":"2003","journal-title":"Gene Ther"},{"key":"10.1016\/j.eururo.2022.09.004_b0100","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41388-018-0407-9","article-title":"Immunoregulatory protein B7\u2013H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation","volume":"38","author":"Liu","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.eururo.2022.09.004_b0105","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3748\/wjg.v21.i6.1804","article-title":"Overexpression of B7\u2013H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3","volume":"21","author":"Zhang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.eururo.2022.09.004_b0110","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.3892\/mmr.2015.4050","article-title":"B7H3 promotes cell migration and invasion through the Jak2\/Stat3\/MMP9 signaling pathway in colorectal cancer","volume":"12","author":"Liu","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.eururo.2022.09.004_b0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7\u2013H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2022.09.004_b0120","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical development of MGC018, a duocarmycin-based antibody\u2013drug conjugate targeting B7\u2013H3 for solid cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2022.09.004_b0125","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1158\/1535-7163.MCT-21-0554","article-title":"DS-7300a, a DNA topoisomerase I inhibitor, DXd-based antibody-drug conjugate targeting B7\u2013H3 exerts potent antitumor activities in preclinical models","volume":"21","author":"Yamato","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2022.09.004_b0130","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","article-title":"Development of an Fc-enhanced anti\u2013B7-H3 monoclonal antibody with potent antitumor activity","volume":"18","author":"Loo","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2022.09.004_b0135","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eururo.2022.09.004_b0140","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.09.004_b0145","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.09.004_b0150","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2022.09.004_b0155","doi-asserted-by":"crossref","unstructured":"Fenor de la Maza MD, Chandran K, Rekowski J, et al. Immune biomarkers in metastatic castration-resistant prostate cancer. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2022.04.004.","DOI":"10.1016\/j.euo.2022.04.004"},{"key":"10.1016\/j.eururo.2022.09.004_b0160","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1172\/JCI125184","article-title":"Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer","volume":"128","author":"Rodrigues","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2022.09.004_b0165","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2014.10.027","article-title":"PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate","volume":"67","author":"Ferraldeschi","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.09.004_b0170","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clcc.2018.05.011","article-title":"Ataxia telangiectasia mutated protein loss and benefit from oxaliplatin-based chemotherapy in colorectal cancer","volume":"17","author":"Sundar","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.eururo.2022.09.004_b0175","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-20-2371","article-title":"Characterizing CDK12-mutated prostate cancers","volume":"27","author":"Rescigno","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2022.09.004_b0180","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.09.004_b0185","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-21-3360","article-title":"HER3 is an actionable target in advanced prostate cancer","volume":"81","author":"Gil","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2022.09.004_b0190","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-17-3571","article-title":"Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC)","volume":"24","author":"Welti","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2022.09.004_b0195","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2022.09.004_b0200","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41591-021-01244-6","article-title":"Transcriptional mediators of treatment resistance in lethal prostate cancer","volume":"27","author":"He","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2022.09.004_b0205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","article-title":"Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression","volume":"23","author":"Chen","year":"2021","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.eururo.2022.09.004_b0210","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2022.09.004_b0215","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","article-title":"Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage","volume":"20","author":"Aran","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.eururo.2022.09.004_b0220","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-015-0088-7","article-title":"nCounter(\u00ae) PanCancer immune profiling panel (NanoString Technologies Inc, Seattle, WA)","volume":"3","author":"Cesano","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.eururo.2022.09.004_b0225","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2022.09.004_b0230","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2022.09.004_b0235","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.immunol.20.091101.091806","article-title":"The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses","volume":"20","author":"Carreno","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.eururo.2022.09.004_b0240","doi-asserted-by":"crossref","first-page":"D506","DOI":"10.1093\/nar\/gky1049","article-title":"UniProt: a worldwide hub of protein knowledge","volume":"47","author":"Consortium TU","year":"2018","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.eururo.2022.09.004_b0245","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/pin.12999","article-title":"High B7\u2013H3 expression is linked to increased risk of prostate cancer progression","volume":"70","author":"Bonk","year":"2020","journal-title":"Pathol Int"},{"key":"10.1016\/j.eururo.2022.09.004_b0250","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.ijrobp.2010.01.061","article-title":"Evaluation of B7\u2013H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer","volume":"79","author":"Parker","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2022.09.004_b0255","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2022.09.004_b0260","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2022.09.004_b0265","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7\u2013H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2022.09.004_b0270","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/pcmr.12599","article-title":"Immunoregulatory protein B7\u2013H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells","volume":"30","author":"Flem-Karlsen","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.eururo.2022.09.004_b0275","doi-asserted-by":"crossref","first-page":"10277","DOI":"10.1073\/pnas.0805458105","article-title":"The contrasting role of B7\u2013H3","volume":"105","author":"Hofmeyer","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2022.09.004_b0280","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41467-021-21615-4","article-title":"Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling","volume":"12","author":"Brady","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2022.09.004_b0285","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41391-021-00331-6","article-title":"Tumor B7\u2013H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer","volume":"24","author":"Amori","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2022.09.004_b0290","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fonc.2018.00264","article-title":"B7H3 as a promoter of metastasis and promising therapeutic target","volume":"8","author":"Dong","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2022.09.004_b0295","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.eururo.2022.09.004_b0300","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2022.09.004_b0305","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/modpathol.2016.95","article-title":"PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes","volume":"29","author":"Rosenbaum","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2022.09.004_b0310","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.09.004_b0315","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00262-019-02393-x","article-title":"The BRCA2 mutation status shapes the immune phenotype of prostate cancer","volume":"68","author":"Jenzer","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eururo.2022.09.004_b0320","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/cncr.34190","article-title":"Association of B7\u2013H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer","volume":"128","author":"Mendes","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2022.09.004_b0325","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor\u2013resistant, EGFR-mutated non\u2013small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2022.09.004_b0330","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.09.004_b0335","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1021\/cr900097c","article-title":"DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition","volume":"109","author":"Pommier","year":"2009","journal-title":"Chem Rev"},{"key":"10.1016\/j.eururo.2022.09.004_b0340","doi-asserted-by":"crossref","first-page":"eaax2625","DOI":"10.1126\/scitranslmed.aax2625","article-title":"BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers","volume":"12","author":"Coussy","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2022.09.004_b0345","first-page":"11","article-title":"Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors","volume":"1835","author":"Tomicic","year":"2013","journal-title":"Biochim Biophy Acta"},{"key":"10.1016\/j.eururo.2022.09.004_b0350","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/MCB.19.3.2109","article-title":"Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts","volume":"19","author":"Stein","year":"1999","journal-title":"Mol Cell Biol"}],"updated-by":[{"DOI":"10.1016\/j.eururo.2023.03.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000}},{"DOI":"10.1016\/j.eururo.2026.07.031","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000}},{"DOI":"10.1016\/j.eururo.2026.07.031","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000}}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822026331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822026331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T20:11:41Z","timestamp":1708459901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283822026331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0302283822026331"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.09.004","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B7-H3 as a Therapeutic Target in Advanced Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}